anti cd137 monoclonal antibody (Celldex Inc)
86
Structured Review
Celldex Inc
anti cd137 monoclonal antibody
Anti Cd137 Monoclonal Antibody, supplied by Celldex Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd137+monoclonal+antibody/varlilumab/us12655159-793-17-22
Average 86 stars, based on 1 article reviews
Anti Cd137 Monoclonal Antibody, supplied by Celldex Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd137+monoclonal+antibody/varlilumab/us12655159-793-17-22
Average 86 stars, based on 1 article reviews
anti cd137 monoclonal antibody - by Bioz Stars,
2026-11
86/100 stars
Images
Related Articles
other:Article Title: Deuterated IRAK degraders and uses thereof Article Snippet: Suitable activators of TLRs include an agonist or activator of TLR9 such as SD-101 (Dynavax). Article Title: MDM2 degraders and uses thereof Article Snippet: Other immuno-oncology agents that may be used in the present invention include urelumab (BMS-663513, Bristol-Myers Squibb), an anti-CD137 monoclonal antibody; Article Title: SMARCA degraders and uses thereof Article Snippet: Agonists or activators of TLR8 which may be used in the present invention include motolimod (VTX-2337, VentiRx Pharmaceuticals) which is being studied for squamous cell cancer of the head and neck (NCTO2124850) and ovarian cancer (NCT02431559). Article Title: SMARCA inhibitors and uses thereof Article Snippet: Agonists or activators of TLR8 which may be used in the present invention include motolimod (VTX-2337, VentiRx Pharmaceuticals) which is being studied for squamous cell cancer of the head and neck (NCT02124850) and ovarian cancer (NCT02431559). Article Title: IRAK degraders and uses thereof Article Snippet: Other immuno-oncology agents that may be used in the present invention include urelumab (BMS-663513, Bristol-Myers Squibb), an anti-CD137 monoclonal antibody; Article Title: GPR84 antagonists and uses thereof Article Snippet: Other immuno-oncology agents that can be used in the present invention include urelumab (BMS-663513, Bristol-Myers Squibb), an anti-CD137 monoclonal antibody; Article Title: SMARCA degraders and uses thereof Article Snippet: Suitable activators of TLRs include an agonist or activator of TLR9 such as SD-101 (Dynavax). Article Title: IRAK degraders and uses thereof Article Snippet: Other immuno-oncology agents that may be used in the present invention include urelumab (BMS-663513, Bristol-Myers Squibb), an anti-CD137 monoclonal antibody; |